From: Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
 |  | All CLL patients†(% or 95% CI) | XPO1-mut (IgHV-U)†(% or 95% CI) | XPO1-wt (IgHV-U)†(% or 95% CI) | XPO1-wt (IgHV-M)†(% or 95% CI) | p value‡ | test |  |
---|---|---|---|---|---|---|---|---|
Demographics | Gender (n, Male) | 649 (69.3%) | 41 (75.9%) | 349 (71.8%) | 258 (65.2%) | 0.630 | χ2 |  |
Rai (n, II–IV) | 167 (27.4%) | 21 (53.8%) | 86 (27.6%) | 60 (23.3%) | 0.199 | χ2 |  | |
Age (median, year) | 57.2 (56.4–58.0) | 52.3 (49.9–55.0) | 57.1 (56.0–58.2) | 58.7 (57.4–59.9) | 0.031 | t-test |  | |
Blood Counts | B2M (median) | 3 (2.8–3.2) | 3.4 (2.6–4.2) | 3.15 (2.9–3.4) | 2.7 (2.5–2.9) | 0.814 | t-test |  |
HGB (median) | 13.1 (12.9–13.3) | 12.5 (11.7–13.3) | 13.1 (12.8–13.4) | 13.4 (13.1–13.7) | 0.562 | t-test |  | |
LDH (median) | 493 (463–523) | 528 (446–610) | 499.5 (453–546) | 473 (438–508) | 0.809 | t-test |  | |
PLT (median) | 167 (159.7–174.3) | 140.5 (113.5–167.5) | 177 (188–166) | 164.5 (154.7–174.3) | 0.149 | t-test |  | |
WBC (median) | 65.35 (57.67–73.03) | 122.95 (82.28–163.62) | 72.3 (61.83–83.60) | 44.8 (35.59–54.01) | 0.041 | t-test |  | |
FISH | del(11q) | 74 (15%) | 3 (11%) | 63 (25%) | 8 (4%) | 0.081 | χ2 |  |
del(13q) | 276 (55%) | 20 (74%) | 116 (45%) | 140 (66%) | 0.003 | χ2 |  | |
del(17p) | 51 (8%) | 1 (3%) | 40 (12%) | 10 (3%) | 0.079 | χ2 |  | |
12 +  | 64 (13%) | 0 (0%) | 42 (16%) | 22 (10%) | 0.011 | χ2 |  | |
CN | 134 (27%) | 7 (26%) | 71 (28%) | 56 (27%) | 0.51 | χ2 |  | |
Mutation Panel | NOTCH1 | 99 (9%) | 9 (13%) | 79 (13%) | 11 (3%) | 0.52 | χ2 |  |
SF3B1 | 52 (15%) | 8 (30%) | 29 (14%) | 15 (12%) | 0.045 | χ2 |  | |
TP53 | 97 (19%) | 5 (16%) | 71 (26%) | 21 (10%) | 0.141 | χ2 |  | |
XPO1 | 72 (6%) | 72 (100%) | 0 (0%) | 0 (0%) | - | - | Â | |
EGR2 | 46 (4%) | 4 (6%) | 32 (5%) | 10 (2%) | 0.51 | χ2 |  | |
MYD88 | 26 (2%) | 0 (0%) | 2 (0.3%) | 24 (6%) | 0.81 | χ2 |  |
 |  | All CLL patients†(% or 95% CI) | XPO1-mut (LP-CLL)†(% or 95% CI) | XPO1-wt (LP-CLL)†(% or 95% CI) | XPO1-wt (IP-CLL)†(% or 95% CI) | XPO1-wt (HP-CLL)†(% or 95% CI) | p value$ | Test |
---|---|---|---|---|---|---|---|---|
 | Multi-Cohort CLL patient characteristics by epigenetic maturation status* | |||||||
Demographics | Gender (count, M) | 659 (69%) | 41 (78.8%) | 310 (70.9%) | 120 (72.7%) | 188 (62.5%) | 0.130 | χ2 |
Rai (count, > 1) | 167 (27.5%) | 21 (56.8%) | 76 (27%) | 36 (35.3%) | 34 (18.2%) | 0.036 | χ2 | |
Age (median, year) | 57.2 (56.4–58.0) | 52.3 (49.6–55.0) | 57.0 (55.8–58.1) | 57.1 (55.2–59.1) | 59.1 (57.7–60.6) | 0.020 | t-test | |
Blood Counts | B2M (median) | 3 (2.8–3.2) | 3.4 (2.6–4.2) | 3.3 (3.0–3.6) | 2.9 (2.5–3.3) | 2.65 (2.4–2.9) | 0.826 | t-test |
HGB (median) | 13.1 (12.9–13.3) | 12.1 (11.3–12.9) | 13 (12.7–13.3) | 13.3 (12.8–13.8) | 13.4 (13.1–13.7) | 0.440 | t-test | |
LDH (median) | 494 (464–524) | 545 (459–631) | 524 (475–573) | 476 (415–537) | 459 (422–496) | 0.936 | t-test | |
PLT (median) | 167 (160–174) | 132 (105–159) | 176 (165–187) | 160 (145–175) | 167 (155–179) | 0.110 | t-test | |
WBC (median) | 65.35 (57.67–73.03) | 124 (81.34–166.66) | 77.3 (65.49–89.11) | 42.45 (26.59–58.31) | 43.65 (33.02–54.28) | 0.056 | t-test | |
FISH | del(11q) | 74 (14%) | 2 (8%) | 62 (26%) | 9 (10%) | 1 (1%) | 0.064 | χ2 |
del(13q) | 288 (56%) | 18 (69%) | 101 (42%) | 64 (72%) | 105 (64%) | 0.0043 | χ2 | |
del(17p) | 52 (7%) | 1 (3%) | 39 (13%) | 5 (4%) | 7 (3%) | 0.196 | χ2 | |
12 +  | 66 (13%) | 0 (0%) | 43 (18%) | 10 (11%) | 13 (8%) | 0.006 | χ2 | |
CN | 140 (27%) | 8 (31%) | 67 (29%) | 18 (20%) | 47 (29%) | 0.54 | χ2 | |
Mutation Panel | NOTCH1 | 105 (9%) | 11 (17%) | 75 (13%) | 11 (6%) | 8 (3%) | 0.289 | χ2 |
SF3B1 | 57 (15%) | 7 (25%) | 28 (15%) | 18 (32%) | 4 (4%) | 0.131 | χ2 | |
TP53 | 101 (19%) | 5 (16%) | 68 (28%) | 13 (14%) | 15 (9%) | 0.214 | χ2 | |
XPO1 | 71 (6%) | 69 (97%) | 0 (0%) | 0 (0%) | 0 (0%) | – | – | |
EGR2 | 48 (4%) | 5 (7%) | 29 (5%) | 9 (5%) | 5 (2%) | 0.32 | χ2 | |
MYD88 | 27 (2%) | 0 (0%) | 0 (0%) | 14 (7%) | 13 (4) | – | – |